DepoMed Inc.
1360 O'Brien Drive
Menlo Park,
CA 94025
United States - Map
Phone: 650-462-5900
Fax: 650-462-9993
Web Site: http://www.depomedinc.com
| Depomed, Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary oral drug delivery technologies in the United States. It markets GLUMETZA for the treatment of type 2 diabetes in the United States, Canada, and Korea; and Proquin XR for treatment of uncomplicated urinary tract infection in the United States. The companys under development products comprise DM-5689, a Phase III clinical trial product for the treatment of menopausal hot flashes; DM-1796, a Phase III clinical trial product for the treatment of postherpetic neuralgia, as well as is in Phase II clinical trail for diabetic peripheral neuropathy; DM-3458, a Phase I clinical trial product for the treatment of gastroesophageal reflux disease; and DM-1992, a Phase I clinical trial product that targets Parkinson's disease. It has collaboration and license agreements with PharmaNova, Inc.; Solvay Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Covidien Ltd.; Santarus, Inc.; Teva Pharmaceuticals USA, Inc.; Patheon, Inc.; Biovail Laboratories Incorporated; LG Life Sciences, Ltd.; Watson Pharmaceuticals, Inc.; and Rottapharm/Madaus S.r.l. The company sells its products to wholesalers and retail pharmacies. Depomed, Inc. was founded in 1995 and is based in Menlo Park, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Carl Pelzel , 58
Chief Exec. Officer, Pres |
N/A
| N/A | Ms. Tammy L. Cameron CPA, 43
VP of Fin. and Controller |
$
272.00K | N/A | Mr. Matthew M. Gosling , 38
VP and Gen. Counsel |
$
449.00K | N/A | Mr. Julian N. Stern , 83
Sec., Director and Member of Nominating & Corp. Governance Committee |
$
30.00K | N/A | Dr. Michael Sweeney M.D., 48
VP of R&D |
$
440.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.34% Nasdaq 0.00%
Profile
